Perrigo To Host Virtual Investor Meetings At The 2021 Barclays Global Consumer Staples Conference

On September 3, 2021 Perrigo Company plc (NYSE; TASE: PRGO), reported that Perrigo President and CEO, Murray S. Kessler, and CFO, Ray Silcock, are scheduled to participate in investor meetings at the Barclays Global Consumer Staples Conference on Thursday, September 9 (Press release, Perrigo Company, SEP 3, 2021, View Source [SID1234587233]). The Company will not be making a formal presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst to Present at Upcoming Investor Conferences

On September 3, 2021 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference (virtual) (Press release, BioCryst Pharmaceuticals, SEP 3, 2021, View Source [SID1234587218]). The H.C. Wainwright presentation will be available on-demand in the Investors section of BioCryst’s website starting at 7:00 a.m. ET on Monday, September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to the live audio webcast of the Wells Fargo presentation and replays of both presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th

On September 3, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021 (Press release, Phio Pharmaceuticals, SEP 3, 2021, View Source [SID1234587234]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phio Company Presentation Details:

Speaker: Dr. Gerrit Dispersyn, President & CEO of Phio Pharmaceuticals
Time/Date: Available starting at 7:00 AM ET on Monday, September 13th
Webcast: Registration (Click Here)
Replay: Interested parties may also access a replay of the Company presentation through the "Investors – Events and Presentations" section of the Company’s website (click here). The webcast will be archived and available on the Company’s website for 90 days.

For more information on the conference, or to schedule a one-on-one meeting, please contact a H.C. Wainwright representative.

Certara Announces Proposed Public Offering of Common Stock

On September 3, 2021 Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, reported a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (Press release, Certara, SEP 3, 2021, View Source [SID1234587219]). Certara is offering 4,500,000 shares of common stock and certain selling stockholders are offering 15,500,000 shares of common stock in the offering. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 3,000,000 additional shares of common stock. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is being made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who are acting as lead joint book-running managers.

A registration statement on Form S-1, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected]; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255 or by email at [email protected].

RAPT Therapeutics to Present at Upcoming Investor Conferences

On September 3, 2021 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, reported that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in the first half of September (Press release, RAPT Therapeutics, SEP 3, 2021, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-present-upcoming-investor-conferences [SID1234587235]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2021 Virtual Healthcare Conference Thursday, September 9, 2021 at 8:00 a.m. EST
H.C. Wainwright 23rd Annual Global Investment Conference presentation available on-demand Monday, September 13, 2021 at 7:00 a.m. EST
To access the live webcasts or subsequent archived recordings of the company presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.